Purkiss Capital Advisors LLC Makes New $375,000 Investment in Stryker Co. (NYSE:SYK)

Purkiss Capital Advisors LLC acquired a new stake in shares of Stryker Co. (NYSE:SYK) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 1,042 shares of the medical technology company’s stock, valued at approximately $375,000.

Other hedge funds also recently made changes to their positions in the company. Capital Wealth Planning LLC grew its holdings in Stryker by 1.9% during the 4th quarter. Capital Wealth Planning LLC now owns 15,376 shares of the medical technology company’s stock valued at $5,536,000 after purchasing an additional 286 shares in the last quarter. Metis Global Partners LLC boosted its position in Stryker by 10.2% in the 4th quarter. Metis Global Partners LLC now owns 16,841 shares of the medical technology company’s stock valued at $6,064,000 after buying an additional 1,561 shares during the last quarter. West Michigan Advisors LLC grew its stake in shares of Stryker by 1.2% during the fourth quarter. West Michigan Advisors LLC now owns 8,675 shares of the medical technology company’s stock valued at $3,131,000 after acquiring an additional 102 shares in the last quarter. US Bancorp DE increased its position in shares of Stryker by 0.5% during the fourth quarter. US Bancorp DE now owns 182,825 shares of the medical technology company’s stock worth $65,829,000 after acquiring an additional 976 shares during the last quarter. Finally, Noesis Capital Mangement Corp lifted its stake in shares of Stryker by 1.0% in the fourth quarter. Noesis Capital Mangement Corp now owns 64,143 shares of the medical technology company’s stock worth $23,095,000 after acquiring an additional 650 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insider Activity at Stryker

In other news, Director Allan C. Golston sold 2,458 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the transaction, the director now owns 14,895 shares of the company’s stock, valued at approximately $5,705,827.65. This represents a 14.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the sale, the director now owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This represents a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

SYK has been the subject of a number of recent analyst reports. Barclays raised their price objective on Stryker from $418.00 to $443.00 and gave the company an “overweight” rating in a research note on Monday, February 10th. Citigroup restated a “buy” rating and issued a $450.00 price target on shares of Stryker in a research note on Wednesday. JPMorgan Chase & Co. upped their price target on shares of Stryker from $420.00 to $445.00 and gave the company an “overweight” rating in a report on Wednesday, January 29th. Wells Fargo & Company raised their price objective on shares of Stryker from $427.00 to $435.00 and gave the stock an “overweight” rating in a report on Wednesday, January 29th. Finally, Argus set a $450.00 target price on shares of Stryker in a research note on Monday, February 3rd. Five research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $422.15.

Stryker Price Performance

Shares of NYSE SYK opened at $386.55 on Friday. Stryker Co. has a 1-year low of $314.93 and a 1-year high of $406.19. The firm has a market capitalization of $147.50 billion, a PE ratio of 49.81, a P/E/G ratio of 2.93 and a beta of 0.96. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The business’s fifty day moving average price is $380.50 and its two-hundred day moving average price is $371.22.

Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period in the previous year, the firm posted $3.46 EPS. On average, research analysts expect that Stryker Co. will post 13.47 EPS for the current year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.87%. Stryker’s dividend payout ratio is presently 43.30%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.